Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
59
ERFSF Quote, Financials, Valuation and Earnings
Last price:
$76.37
Seasonality move
:
12.86%
Day range:
$73.80 - $77.12
52-week range:
$48.55 - $86.20
Dividend yield:
1.51%
P/E ratio:
28.18x
P/S ratio:
1.83x
P/B ratio:
56.92x
Volume:
2.5K
Avg. volume:
5.2K
1-year change:
40.88%
Market cap:
$14.3B
Revenue:
$8.2B
EPS (TTM):
$2.87
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ERFSF
Eurofins Scientific SE
|
-- | -- | -- | -- | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$283.5M | $0.08 | 16.03% | -30.17% | $31.85 |
|
AGEN
Agenus, Inc.
|
$129.5M | $1.80 | 34.29% | -36.28% | $12.33 |
|
ALVO
Alvotech
|
$140.8M | $0.06 | 28.15% | -83.49% | $14.00 |
|
AUNA
Auna SA
|
$340.1M | $0.24 | 20.77% | 82.77% | $7.20 |
|
PROCF
Sofgen Pharma SA
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ERFSF
Eurofins Scientific SE
|
$76.37 | -- | $14.3B | 28.18x | $0.68 | 1.51% | 1.83x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.32 | $31.85 | $3.8B | 9.79x | $0.00 | 0% | 3.54x |
|
AGEN
Agenus, Inc.
|
$3.40 | $12.33 | $133.3M | -- | $0.00 | 0% | 0.92x |
|
ALVO
Alvotech
|
$3.62 | $14.00 | $1.2B | 37.55x | $0.00 | 0% | 1.94x |
|
AUNA
Auna SA
|
$5.62 | $7.20 | $425M | 8.38x | $0.00 | 0% | 0.35x |
|
PROCF
Sofgen Pharma SA
|
$0.1100 | -- | $256M | -- | $0.00 | 0% | 0.03x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ERFSF
Eurofins Scientific SE
|
43.41% | 0.766 | -- | 1.08x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
AGEN
Agenus, Inc.
|
525.02% | -0.070 | 321.54% | 0.03x |
|
ALVO
Alvotech
|
115.99% | 3.729 | 50.24% | 0.54x |
|
AUNA
Auna SA
|
69.55% | -0.634 | 263.01% | 0.85x |
|
PROCF
Sofgen Pharma SA
|
-- | 677.906 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ERFSF
Eurofins Scientific SE
|
-- | -- | 5.27% | 8.55% | -- | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AGEN
Agenus, Inc.
|
$33.6M | $14.4M | -3.83% | -- | 42.1% | -$16.6M |
|
ALVO
Alvotech
|
$78.7M | $1.2M | 7.33% | -- | 1.05% | -$84M |
|
AUNA
Auna SA
|
$126.7M | $39.6M | 1.92% | 6% | 11.83% | $16.7M |
|
PROCF
Sofgen Pharma SA
|
-- | -- | -- | -- | -- | -- |
Eurofins Scientific SE vs. Competitors
-
Which has Higher Returns ERFSF or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Eurofins Scientific SE's net margin of 96.33%. Eurofins Scientific SE's return on equity of 8.55% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About ERFSF or ACAD?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 42.7%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Eurofins Scientific SE, analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is ERFSF or ACAD More Risky?
Eurofins Scientific SE has a beta of 0.711, which suggesting that the stock is 28.889% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock ERFSF or ACAD?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.51%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or ACAD?
Eurofins Scientific SE quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Eurofins Scientific SE's net income of -- is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Eurofins Scientific SE's price-to-earnings ratio is 28.18x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.83x versus 3.54x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.83x 28.18x -- -- ACADACADIA Pharmaceuticals, Inc.3.54x 9.79x $284M $273.6M
-
Which has Higher Returns ERFSF or AGEN?
Agenus, Inc. has a net margin of -- compared to Eurofins Scientific SE's net margin of -31.03%. Eurofins Scientific SE's return on equity of 8.55% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B AGENAgenus, Inc.98.26% -$0.30 $57M -
What do Analysts Say About ERFSF or AGEN?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 262.75%. Given that Agenus, Inc. has higher upside potential than Eurofins Scientific SE, analysts believe Agenus, Inc. is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 AGENAgenus, Inc.2 1 0 -
Is ERFSF or AGEN More Risky?
Eurofins Scientific SE has a beta of 0.711, which suggesting that the stock is 28.889% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.604, suggesting its more volatile than the S&P 500 by 60.406%.
-
Which is a Better Dividend Stock ERFSF or AGEN?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.51%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or AGEN?
Eurofins Scientific SE quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $34.2M. Eurofins Scientific SE's net income of -- is lower than Agenus, Inc.'s net income of -$10.6M. Notably, Eurofins Scientific SE's price-to-earnings ratio is 28.18x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.83x versus 0.92x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.83x 28.18x -- -- AGENAgenus, Inc.0.92x -- $34.2M -$10.6M
-
Which has Higher Returns ERFSF or ALVO?
Alvotech has a net margin of -- compared to Eurofins Scientific SE's net margin of -4.62%. Eurofins Scientific SE's return on equity of 8.55% beat Alvotech's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B ALVOAlvotech69.22% -$0.02 $1.1B -
What do Analysts Say About ERFSF or ALVO?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand Alvotech has an analysts' consensus of $14.00 which suggests that it could grow by 286.74%. Given that Alvotech has higher upside potential than Eurofins Scientific SE, analysts believe Alvotech is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 ALVOAlvotech3 1 0 -
Is ERFSF or ALVO More Risky?
Eurofins Scientific SE has a beta of 0.711, which suggesting that the stock is 28.889% less volatile than S&P 500. In comparison Alvotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ERFSF or ALVO?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.51%. Alvotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. Alvotech pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or ALVO?
Eurofins Scientific SE quarterly revenues are --, which are smaller than Alvotech quarterly revenues of $113.7M. Eurofins Scientific SE's net income of -- is lower than Alvotech's net income of -$5.3M. Notably, Eurofins Scientific SE's price-to-earnings ratio is 28.18x while Alvotech's PE ratio is 37.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.83x versus 1.94x for Alvotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.83x 28.18x -- -- ALVOAlvotech1.94x 37.55x $113.7M -$5.3M
-
Which has Higher Returns ERFSF or AUNA?
Auna SA has a net margin of -- compared to Eurofins Scientific SE's net margin of -5.65%. Eurofins Scientific SE's return on equity of 8.55% beat Auna SA's return on equity of 6%.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B AUNAAuna SA37.86% -$0.63 $1.6B -
What do Analysts Say About ERFSF or AUNA?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand Auna SA has an analysts' consensus of $7.20 which suggests that it could grow by 28.11%. Given that Auna SA has higher upside potential than Eurofins Scientific SE, analysts believe Auna SA is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 AUNAAuna SA4 2 0 -
Is ERFSF or AUNA More Risky?
Eurofins Scientific SE has a beta of 0.711, which suggesting that the stock is 28.889% less volatile than S&P 500. In comparison Auna SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ERFSF or AUNA?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.51%. Auna SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. Auna SA pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or AUNA?
Eurofins Scientific SE quarterly revenues are --, which are smaller than Auna SA quarterly revenues of $334.7M. Eurofins Scientific SE's net income of -- is lower than Auna SA's net income of -$18.9M. Notably, Eurofins Scientific SE's price-to-earnings ratio is 28.18x while Auna SA's PE ratio is 8.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.83x versus 0.35x for Auna SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.83x 28.18x -- -- AUNAAuna SA0.35x 8.38x $334.7M -$18.9M
-
Which has Higher Returns ERFSF or PROCF?
Sofgen Pharma SA has a net margin of -- compared to Eurofins Scientific SE's net margin of --. Eurofins Scientific SE's return on equity of 8.55% beat Sofgen Pharma SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B PROCFSofgen Pharma SA-- -- -- -
What do Analysts Say About ERFSF or PROCF?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand Sofgen Pharma SA has an analysts' consensus of -- which suggests that it could grow by 4445.46%. Given that Sofgen Pharma SA has higher upside potential than Eurofins Scientific SE, analysts believe Sofgen Pharma SA is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 PROCFSofgen Pharma SA0 0 0 -
Is ERFSF or PROCF More Risky?
Eurofins Scientific SE has a beta of 0.711, which suggesting that the stock is 28.889% less volatile than S&P 500. In comparison Sofgen Pharma SA has a beta of 62.272, suggesting its more volatile than the S&P 500 by 6127.174%.
-
Which is a Better Dividend Stock ERFSF or PROCF?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.51%. Sofgen Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. Sofgen Pharma SA pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or PROCF?
Eurofins Scientific SE quarterly revenues are --, which are smaller than Sofgen Pharma SA quarterly revenues of --. Eurofins Scientific SE's net income of -- is lower than Sofgen Pharma SA's net income of --. Notably, Eurofins Scientific SE's price-to-earnings ratio is 28.18x while Sofgen Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.83x versus 0.03x for Sofgen Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.83x 28.18x -- -- PROCFSofgen Pharma SA0.03x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
72
RGC alert for Apr 2
Regencell Bioscience Holdings Ltd. [RGC] is up 32.32% over the past day.
Sell
27
RH alert for Apr 2
RH [RH] is down 19.29% over the past day.
Sell
43
AXTI alert for Apr 2
AXT, Inc. [AXTI] is down 17.29% over the past day.
